News

BioSculpture Technology, Inc. IPO to Develop a Disruptive Technology that May Solve $2 Trillion Yearly Obesity and Type 2 Diabetes Problem



September 1, 2016: BioSculpture Technology, Inc. has a qualifed tier 2 Regulation A Offering to commercialize its patented minimally invasive EVL® device and method for the endoscopic removal of visceral or “belly” fat, as a new treatment of obesity, metabolic syndrome and type 2 Diabetes mellitus. Scientific research has confirmed that excessive visceral fat within the abdominal cavity causes metabolic syndrome and type 2 diabetes, decreasing the quality of human life and shortening the lives of those we love.


http://www.bst-ipo.com/


https://youtu.be/5xC8pvNmMeI